AAP
SKYE icon

Arax Advisory Partners’s Skye Bioscience SKYE Stock Holding History

Arax Advisory Partners’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$35 – 4591
2025
Q3 		$35 Buy
+1
New +$30 ﹤0.01% 3552

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Arax Advisory Partners's SKYE Position: Q4 2025 in Review

Arax Advisory Partners sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 1 share — an estimated $35 sold.

Arax Advisory Partners first reported a position in SKYE in Q3 2025 and held it in 1 quarter. The position peaked at $35 in Q3 2025. 42 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Arax Advisory Partners reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 1 Skye Bioscience share in Q4 2025, an estimated $35.
  • Arax Advisory Partners first reported a position in Skye Bioscience in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Skye Bioscience position peaked at $35 in Q3 2025.
  • 42 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.